Journal of Immunology Research / 2013 / Article / Tab 2

Research Article

Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus

Table 2

Disease characteristics of SLE before abatacept treatment.

Case numberDuration of SLE (month)Major current disease manifestations other than arthritisMajor previous disease manifestations other than arthritisCTD other than RA or SLEANAAnti-DNA antibody (U/mL)Other autoantibodiesIgG (mg/dL)C3 (mg/dL)C4 (mg/dL)CH50 (U/mL)SLEDAI

12Low grade fever, rash, anemia, leukocytopeniaFever, rash, anemia, leukocytopeniaSS, chronic thyroiditis>128029.5Ro, LA, TPO2285811436.87
2565RashRash, leukocytopenia, pericarditis, pleuritisSS>128047.8Ro, La1265871231.112
320NoneFever, anemia, leukocytopeniaNone32028.3U1-RNP, Cardiolipin1939273<5.08
4151RashRash, leukocytopeniaScleroderma, chronic thyroiditis>128016.8Sm, U1-RNP, TPO16251114147.56
5420NoneFever, rash, severe thrombocytopeniaSS16010.1Ro, La228566417.46
696NoneFever, rash, myositis, ILDSS3204.0U1-RNP, Ro15981524045.14

SLE: systemic lupus erythematosus; CTD: connective tissue disease; ANA: antinuclear antibody; IgG: immunoglobulin G; SLEDAI: systemic lupus erythematosus disease activity index; ILD: interstitial lung disease; SS: Sjogren’s syndrome; APS: antiphospholipid syndrome; LA: lupus anticoagulant; TPO: thyroid peroxidase; RNP: ribonucleoprotein.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.